Renaissance Technologies (RenTech)'s ADCT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 299,278 shares of ADC Therapeutics SA (ADCT) worth $1.12 M, representing 0.00% of the portfolio. First purchased in 2022-Q2, this short-term holding has been held for 4 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in ADCT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 299,278 shares. Largest reduction occurred in Q4 2022, reducing 71,100 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s ADC Therapeutics (ADCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADC Therapeutics (ADCT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +299,278 | New Buy | 299,278 | $3.75 |
| Q4 2022 | -71,100 | Sold Out | 0 | $0.00 |
| Q3 2022 | -8,800 | Reduce 11.01% | 71,100 | $4.82 |
| Q2 2022 | +79,900 | New Buy | 79,900 | $7.95 |
Renaissance Technologies (RenTech)'s ADC Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased ADC Therapeutics SA (ADCT) in Q2 2022, acquiring 79,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held ADC Therapeutics SA (ADCT) for 4 quarters since Q2 2022.
Renaissance Technologies (RenTech)'s largest addition to ADC Therapeutics SA (ADCT) was in Q1 2026, adding 299,278 shares worth $1.12 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 299,278 shares of ADC Therapeutics SA (ADCT), valued at approximately $1.12 M.
As of the Q1 2026 filing, ADC Therapeutics SA (ADCT) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in ADC Therapeutics SA (ADCT) was 299,278 shares, as reported at the end of Q1 2026.